Table 6.
Comparing the Data from Previous Studies.
| Ionesco et al. | Elesber et al. | Khalighi et al. | Looi et al. 2012 | |
|---|---|---|---|---|
| Number of Patients | 27 | 100 | 12 | 100 |
| Mean Age (years) | 68 ± 14 | 66 ± 13 | 64 ± 15 | 65 ± 11 |
| Follow/up Duration | 2.25 ±1.3 years | 4.7 ±4.2 years | 8.3 ± 3.6 years | 3.0 ±1.7 |
| Patients Antiplatelet agent | 33% | 50% | 83% | 90 |
| Patients on BB | 33% | 51% | 83% | 65% |
| Patients on ACE I/ARB | 41% | 74% | 83% | 63% |
| Patients on Statin | 30% | 32% | 67% | 69% |
| Overall patients on optimal medical therapy | 34.3% | 51.8% | 79.0% | |
| Results | ||||
| Chest pain | 2 | 31 | 4 | 78% |
| Hospitalization for cardiac complaints | 8 | 12 | 1 | 26% |
| Recurrence of TC | 2 | 10 | 0 | 7 (7%) |
| Mortality | 4 | 17 | 0 | 4 (4%) |
| Morbidity/Mortality | 14 (52%) | 29 (29%) * | 1 (8%) | 26 (26%) |
Morbidity and mortality = hospitalization for cardiac reasons, death from any cause; * event rate is 39% if we include recurrence of TC.